|
Novartis to expand its human vaccines presence in China
|
06 November 2009 |
|
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
|
04 November 2009 |
|
Novartis on track to deliver Influenza A (H1N1) vaccine for the US
|
02 November 2009 |
|
Novartis delivers strong new product momentum and operational performance
|
27 October 2009 |
|
Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec®
|
21 October 2009 |
|
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM)
|
13 October 2009 |
|
Sandoz launches somatropin, the first-ever Japanese biosimilar
|
06 October 2009 |
|
Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
|
02 October 2009 |
|
Novartis bronchodilator QAB149 recommended for approval in European Union
|
28 September 2009 |
|
Novartis investigational bronchodilator QAB149 compared to tiotropium
|
17 September 2009 |